Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight back with other than more restrictions or boosters of authorized shots such as those from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) […]
Disruptive Technologies Powering the IoT Connectivity Industry Intensifying as Demand for Smart Devices is Booming
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The Internet of Things (IoT) connectivity market has emerged from the pandemic ‘s hurdles and is projected to ramp up its growth curve starting in 2022. Rapid investment in sensing technology for automating industrial operations is driving IoT connectivity market revenue growth. Growing […]
SPYR Technologies’ Applied Magix Introduces Limited Time Special Pricing and Expands Airing Schedule of Its Successful MagixDrive Commercial
The Woodlands, TX – March 24, 2022 – SPYR, Inc. (OTCQB: SPYR), dba SPYR Technologies (https://spyr.com/) (“SPYR” or the “Company”), a technology company whose subsidiary, Applied Magix, Inc., develops and resells Apple® ecosystem compatible products in the growing multibillion-dollar IoT smart home and connected car markets, introduces Limited Time Special Pricing of $99.99 for MagixDrive (stand-alone) […]
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diagnosed with breast cancer across the globe, the need […]
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort
First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep’s development in large and rapidly growing pharmaceutical markets, including China, Hong Kong, Macau, Taiwan, Singapore, and South Korea Final cohort’s dosing regimen is equivalent […]
